The addition of ivosidenib to azacitidine improved outcomes for certain patients with acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.The regimen ...

Ivosidenib modestly extended OS among patients with previously treated isocitrate dehydrogenase 1-mutated advanced cholangiocarcinoma, according to final results of the phase 3 ClarIDHy trial ...

A phase 3 trial evaluating ivosidenib plus azacitidine in adults with previously untreated IDH1-mutated AML showed that it met all endpoints.

Find out how to take Ivosidenib(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments ...

But recent medical breakthroughs-including the recent approval of targeted therapies in India like Ivosidenib for IDH1 mutated AML - may change the narrative. "Acute Myeloid Leukemia is a disease ...

Ivosidenib tablets are used to treat acute myeloid leukemia, a blood and bone marrow cancer in adults with a specific mutation whose condition has worsened or shown resistance with other medicines.

Ivosidenib and azacitidine Ivosidenib is a targeted cancer drug. It is also known as Tibsovo. Azacitidine is a chemotherapy drug. It is also called Vidaza. You pronounce ivosidenib as ...

Two-fold increase in PFS with postoperative ivosidenib holds up in placebo-controlled trial ...